Using Gene Expression Ratios to Predict Outcome Among Patients With Mesothelioma

Gordon, Gavin J.; Jensen, Roderick V.; Hsiao, Li Li; Gullans, Steven R.; Blumenstock, Joshua; Richards, William G.; Jaklitsch, Michael T.; Sugarbaker, David J.; Bueno, Raphael

doi:10.1093/jnci/95.8.598

Cited by 173 publications

(160 citation statements)

References 19 publications

Supporting

Mentioning

145

Contrasting

Unclassified

Order By: Relevance

“…Singhal et al (2003) identified genes differentially expressed in tumors compared with normal tissue. Pass et al (2004) and Gordon et al (2003) have identified distinct signatures of prognosis in resected pleural mesothelioma, which interestingly were independent of histology subtype. More recently, Gordon et al (2005) used unsupervised clustering to identify three groups of tumors, two of which were comprised primarily of epithelial and biphasic tumors, respectively.…”

Section: Discussionmentioning

confidence: 95%

Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin–proteasome pathway as a therapeutic target in poor prognosis tumors

et al. 2006

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 95%

Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin–proteasome pathway as a therapeutic target in poor prognosis tumors

et al. 2006

View full text Add to dashboard Cite

“…According to this score, only 2 adenoma specimens out of the 26 analyzed (7%) were misclassified, as their score was comparable to that of PaC group. The use of genes-score or gene-ratios is a relative new strategy for the identification of patients with different prognosis or disease outcome (Gordon et al 2003, Paik et al 2004, Stamatopoulos et al 2009). This observation implies that not single gene but rather small gene-sets could be useful prognostic or predictive factor even when a highly heterogeneous sample population, as parathyroid adenomas, is investigated.…”

Section: S Corbetta V Vaira Et Al: Mir In Parathyroid Carcinomasmentioning

confidence: 99%

Differential expression of microRNAs in human parathyroid carcinomas compared with normal parathyroid tissue

Corbetta

Vaira

Guarnieri

et al. 2010

Endocrine-Related Cancer

132

117

View full text Add to dashboard Cite

Parathyroid carcinoma (PaC) is a rare cause of primary hyperparathyroidism. Though the loss of the oncosuppressor CDC73/HRPT2 gene product, parafibromin, has been involved in the hyperparathyroidism-jaw tumor syndrome and in a consistent set of sporadic PaCs, parathyroid carcinogenesis remains obscure. MicroRNAs are a new class of small, non-coding RNAs implicated in development of cancer, since their deregulation can induce aberrant expression of several target genes. The aim of the present study was to identify differentially expressed microRNAs in parathyroid cancers compared with normal tissues. We performed a TaqMan low-density array profiling of four parathyroid cancers harboring CDC73 inactivating mutations and negative for parafibromin immunostaining. Their microRNA profiling was compared with that of two normal parathyroid biopsies. Out of 362 human microRNAs assayed, 279 (77%) were successfully amplified. Fourteen and three microRNAs were significantly down-and over-expressed in parathyroid cancers respectively. Of these, miR-296 and miR-139 were down-regulated, and miR-503 and miR-222 were over-expressed with a null false discovery rate. Carcinomas could be discriminated from parathyroid adenomas by a computed score based on the expression levels of miR-296, miR-222, and miR-503 as miR-139 was similarly down-regulated in both cancers and adenomas. Finally, miR-296 and miR-222 levels negatively correlated with mRNA levels of the hepatocyte growth factor receptor-regulated tyrosine kinase substrate and p27/kip1 levels respectively. These results suggest the existence of an altered microRNA expression pattern in PaCs together with a potential role of miR-296 as novel oncosuppressor gene in these neoplasia.

show abstract

“…Tetraspanins are characterized by four transmembrane domains delimiting two extracytoplasmic regions of unequal size (13). Elevated expression of TM4SF1 has been reported in several tumor types, and is implicated in cancer cell migration and patient outcome, but it adopts different roles that are dependent upon tumor type (14)(15)(16)(17). In addition, TM4SF1 is important for endothelial cell migration and tumor angiogenesis (18,19), although the underlying mechanism of its function is not clear, especially in pancreatic cancer.…”

Section: Introductionmentioning

confidence: 99%

TM4SF1 as a prognostic marker of pancreatic ductal adenocarcinoma is involved in migration and invasion of cancer cells

Zheng

Ohuchida

Chen

et al. 2015

International Journal of Oncology

View full text Add to dashboard Cite

Abstract. The cell surface protein Transmembrane 4 L6 family member 1 (TM4SF1) has been detected in various tumors, and its expression on tumor cells is implicated in cancer cell metastasis and patient prognosis. The role of TM4SF1 in malignant tumors remains poorly understood, particularly in pancreatic cancer. We performed immunohistochemical staining to analyze the expression of TM4SF1 in resected pancreatic tissues and investigated the correlation between TM4SF1 expression and prognosis. The function of TM4SF1 in the invasion and migration of pancreatic cancer cells was analyzed in vitro using an RNA interference technique. In pancreatic cancer tissues, TM4SF1 expression was detected in cancer cells, and patients with high tumor levels of TM4SF1 showed longer survival times than those with low TM4SF1 levels (P=0.0332). In vitro, reduced TM4SF1 expression enhanced the migration (P<0.05) and invasion (P<0.05) of pancreatic cancer cells partially via decreased E-cadherin expression. TM4SF1 protein levels were also reduced after TGF-β1-induced epithelial-mesenchymal transition (EMT). TM4SF1 expression is associated with better prognosis in pancreatic cancer. Loss of TM4SF1 contributes to the invasion and migration of pancreatic cancer cells.

show abstract

Using Gene Expression Ratios to Predict Outcome Among Patients With Mesothelioma

Abstract: Gene expression ratio-based analysis accurately predicts treatment-related outcome in mesothelioma samples. This technique could impact the clinical treatment of mesothelioma by allowing the preoperative identification of patients with widely divergent prognoses.

Cited by 173 publications

References 19 publications

Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin–proteasome pathway as a therapeutic target in poor prognosis tumors

Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin–proteasome pathway as a therapeutic target in poor prognosis tumors

Differential expression of microRNAs in human parathyroid carcinomas compared with normal parathyroid tissue

TM4SF1 as a prognostic marker of pancreatic ductal adenocarcinoma is involved in migration and invasion of cancer cells

Contact Info

Product

Resources

About